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ASP is a serine protease secreted by Aeromonas sobria, a sepsis-causing bacterium, and induces sep-
sis-mimicking disorders through plasma protein cleavage. The pathogen also secretes nASP that has
a nick in the carboxy-terminal region. Compared with single-chain ASP (sASP), nASP had near-
equivalent activity for small peptide substrates but was less proteolytic. Surprisingly, nASP cleaved
proteins more in plasma and was inhibited by human a2-macroglobulin more slowly than sASP.
Retarded inhibition by a2-macroglobulin allows nASP to keep proteolytic activity for longer in the
host and exacerbate disorders at Aeromonas sobria infection sites. nASP may be an evolutional form
to augment ASP virulence.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Aeromonas species, facultative anaerobic gram-negative rods,
are distributed worldwide in aquatic environments [1] and com-
monly cause gastroenteritis [2,3]. Aeromonas infections via wounds
or the digestive tract often develop into systemic infections, such
as peritonitis, meningitis, pneumonia and septicemia [3]. Aeromo-
nas species release a number of putative virulence factors, includ-
ing hemolysins, enterotoxins and proteases [4]. We puriﬁed a
65 kDa Aeromonas sobria serine protease [5], referred to as ASP,
from culture supernatants of A. sobria that is most frequently iso-
lated from patient blood [6] and is more virulent than other Aero-
monas species [7]. ASP is a single-chain protein composed of 600
amino acid residues (sASP) and is a kexin-like serine protease
belonging to the subtilisin family (subtilases) [8] (Fig. 1). The sub-
strate speciﬁcity ASP is similar to Kex2 [9] that possesses a high de-
gree of speciﬁcity for dibasic residues [10]. ASP releases
anaphylatoxin C5a [11] from the ﬁfth component of the comple-
ment system. C5a is a potent chemoattractant [12] that causeschemical Societies. Published by E
ura).accumulation of neutrophils forming pus. ASP induces vascular
leakage through activation of the plasma kallikrein/kinin system
and lowers blood pressure [13]. ASP impairs the coagulation sys-
tem by activating prothrombin [9] and degrading ﬁbrinogen [14].
These ASP activities to induce inﬂammation, shock and coagulation
disorder, suggest that ASP is a potent virulence factor in diseases
caused by A. sobria infection.
This pathogen also secretes an isoform of ASP (nASP) that has a
nick at the peptide bond between Gln519 and Leu520 and the cut off
carboxy-terminal peptide (81 amino acid residues) is non-cova-
lently attached to the protease body [15] (Fig. 1). As the nick is lo-
cated at the junction of the protease body and the downstream
ASP-speciﬁc domains is situated close to the catalytic triad Asp78,
His115 and Ser336 (Fig. 1), it is possible that the nick affects sub-
strate access to the catalytic domain and ASP activity for proteins
including the bait region of a2-macroglobulin (a2-MG), the major
ASP inhibitor in human plasma [16]. a2-MG inhibits ASP immedi-
ately after cleavage of the bait region by the protease [17], thus
alteration of ASP activity may change inhibition efﬁciency of the
inhibitor for ASP, modifying ASP activity in vivo. To investigate ef-
fects of the nick on ASP, we compared nASP with sASP in protease
activity and inhibition by a2-MG.lsevier B.V. All rights reserved.
Fig. 1. Overall structure of sASP and nASP. The N-terminal domain including the catalytic site and the C-terminal P-domain are shown in yellow and purple, respectively. The
catalytic site is shown with a bound substrate model (Lys-Lys-Glu) (green sticks). The C-terminal fragment of 81 amino acid residues from the nick in ASP is shown in cyan.
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2.1. Materials
4-Methylcoumaryl-7-amide (MCA) substrates were obtained
from the Peptide Institute (Minoh, Japan). Human prothrombin
and Thromborel S were purchased from Enzyme Research Labora-
tories (South Bend, IN, USA) and Dade Behring (Eschborn, Ger-
many), respectively. Human a-thrombin, ﬁbrinogen and a2-MG
were obtained from Calbiochem (San Diego, CA, USA). Other chem-
icals were purchased from Wako Pure Chemical Industries (Osaka,
Japan). Normal human plasma was prepared by centrifugation of a
mixture of nine volumes of freshly drawn blood from healthy vol-
unteers and one volume of 3.8% (w/v) sodium citrate.
2.2. Puriﬁcation of ASP
sASP and nASP were puriﬁed from the culture supernatant of A.
sobria strain T94 harboring pSA19-5528, as previously described
[5]. Finally, sASP and nASP were puriﬁed using a hydroxyapatite
column in an HPLC system and separated with a linear gradient
of 1–100 mM phosphate buffer. SDS–PAGE analysis of sASP and
nASP showed them to be homogeneous with molecular masses
of 64 and 58 kDa, respectively [15]. Matrix-assisted laser
desorption ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS) and amino acid sequencing analysis showed that nASP
was identical to sASP, except that it was nicked between Gln519
and Leu520 [15].
2.3. Measurement of enzymatic activity
Ten microliters of MCA substrate (10 mM) was added to 600 ll
of ASP solution (10 nM in 50 mM Tris–HCl, pH 7.4, containing
0.1 M NaCl) and incubated at 37 C. In the prothrombin activation
assay, 90 ll of human prothrombin at its plasma concentration
(1.1 M) [18] was dissolved in 50 mM Tris–HCl, pH 7.4, containing
0.1 M NaCl and incubated with 10 ll protease at 37 C for various
periods. Then, 500 ll of 0.1 M Tris–HCl, pH 7.6, containing 150 mM
NaCl was added to the mixture, followed by 10 ll of Boc-As-
p(OBzl)-Pro-Arg-MCA (10 mM) [9]. The release of 7-amino-4-
methyl coumarin (AMC) (ﬂuorescence at 440 nm with excitationat 380 nm) was measured at 37 C using a ﬂuorescence spectro-
photometer (Model 650-40, Hitachi, Tokyo, Japan), which was
monitored with a recorder.
2.4. Clotting assay
Plasma coagulation time was measured with KC4D (Trinity Bio-
tech, Bray, Ireland), according to published methods [9,14,19]. In
the thrombin time (TT) assay, 90 ll of citrated human plasma or
ﬁbrinogen at plasma concentration [18] {3 mg/ml in 10 mM Tris–
HCl, pH 7.5, containing 150 mM NaCl (TBS)} was incubated in a
plastic cell with 10 ll of protease at 37 C for 3 min. The effect of
a2-MG on ﬁbrinogen degradation by ASP was investigated by add-
ing 10 ll of 300 nM ASP to 90 ll of the ﬁbrinogen mixture (3 mg/
ml) with increasing concentrations of a2-MG. Then, 100 ll human
thrombin (5 U/ml) was added to initiate clotting [20,21]. In the
prothrombin time (PT) assay, 45 ll of human citrated plasma and
5 ll of protease were incubated in a plastic cell at 37 C for
3 min, followed by the addition of 50 ll Thromborel S to initiate
clotting. The controls were TBS or ASP that had been boiled for
5 min.
2.5. SDS–PAGE
ASP (70 nM) and a2-MG (84 nM) were incubated at 37 C, fol-
lowed by the addition of 10 mM diisopropylﬂuorophosphate
(DFP) for various time periods. Thirty microliters of each sample
was mixed with 5 ll of SDS-buffer and boiled for 5 min, being ana-
lyzed by SDS–PAGE using an 8% polyacrylamide gel. A Silver Stain II
kit (Wako Biochemicals, Osaka, Japan) was used for protein
staining.
2.6. Fluorescence correlation spectroscopy (FCS)
Diffusion time (DT) of a ﬂuorophore correlates its molecular
weight; DT of a big molecule is longer than that of a small mole-
cule. FCS determines DT by correlation analysis of ﬂuorophore ﬂuc-
tuation. Fluorescence-labeling of ASP and FCS were performed
according to the method described previously [16]. To observe
ASP trapping by a2-MG, ﬂuorescence-labeled ASP (5 nM) was
mixed with human plasma diluted ﬁvefold with PBS and ﬂuores-
Table 1
Small substrate cleavage by single-chain ASP and nicked ASP.
AMC release
(nMmin1)
Ratio (nASP:sASP)
nASP sASP
1 Boc-Glu-Lys-Lys-MCA 74.5 74.5 1.00
2 Pyr-Arg-Thr-Lys-Arg-MCA 61.0 63.5 0.92
3 Boc-Arg-Val-Arg-Arg-MCA 8.7 9.6 0.91
4 Boc-Leu-Lys-Arg-MCA 7.0 6.8 1.03
5 Boc-Gly-Arg-Arg-MCA 1.5 1.4 1.07
6 Boc-Ile-Glu-Gly-Arg-MCA 63.0 66.0 0.95
7 Boc-Val-Pro-Arg-MCA 7.0 7.6 0.92
8 Boc-Asp(OBzl)-Pro-Arg-MCA 4.6 4.5 1.02
9 Boc-Glu(OBzl)-Ala-Arg-MCA 3.3 3.1 1.06
10 Boc-Phe-Ser-Arg-MCA 2.1 1.8 1.17
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the ﬂuorescence intensity ﬂuctuation was performed using analy-
sis software (Hamamatsu Photonics, Hamamatsu, Japan). The ratio
of the larger DT value was potted chronologically and the approx-
imation curve was obtained by polynominal ﬁtting using MS Excel
software. Velocity of complex formation of ASP with a2-MG in
plasma was estimated by the time when the ratio of the complex
became 50%.
2.7. Statistics
Statistical analysis was performed using the unpaired Student’s
t-test. Values were expressed as the mean ± S.D. (n = 4).11 Z-Phe-Arg-MCA 0 0
12 Arg-MCA 0 0
13 Boc-Val-Leu-Lys-MCA 5.4 4.9 1.10
14 Suc-Ala-Ala-Pro-Phe-MCA 23.1 25.5 0.91
15 Suc(OMe)-Ala-Ala-Pro-Val-MCA 0.6 0.7 0.86
16 Suc-Ala-Pro-Ala-MCA 0 0
17 Gly-Pro-MCA 0 0
18 Suc-Gly-Pro-Leu-Gly-Pro-MCA 0 0
19 Ac-Asp-Glu-Val-Asp-MCA 0 0
20 Z-Leu-Leu-Glu-MCA 0 0
Boc, t-buthyloxycarbonyl; Pyr, L-pyroglutamyl; Ac, acetyl; Asp(OBzl), [–(2S)-2-
amino-3-(benzylocarbonyl)propionyl]; Glu(OBzl), [–(2S)-2-amino-3-(benzylocar-
bonyl)butanoyl]; Z, benzyloxycarbonyl; Suc, succinyl; Suc(OMe), N-
methoxysuccinyl.3. Results
3.1. Cleavage of oligopeptide substrates by nASP
nASP protease activity was characterized by investigating the
substrate speciﬁcity of nASP using various oligopeptide substrates.
nASP preferentially cleaved substrates with paired basic amino
acid residues at the P1 and P2 sites (Table 1), which showed that
nASP has the same kexin-like protease property as sASP [9]. nASP
also cleaved substrates with Arg at the P1 site, but the efﬁciency
varied with residues at P2 and P3 sites. A preference for hydropho-
bic amino acid residues at the P4 site and the capability of cleaving
a substrate with Phe at the P1 site [9,22,23] indicated subtilisin-
like substrate speciﬁcity for nASP as sASP. nASP was unable to
cleave substrates with Ala, Pro, Asp or Glu at the P1 site. The result
that nASP was near-identical to sASP in substrate speciﬁcity proﬁle
and cleaving efﬁciency indicated a negligible effect of the nick on
ASP activity for small peptide substrates.
3.2. Cleavage of proteins by nASP
Next, nASP was examined for protein cleavage. To investigate
ﬁbrinogen cleavage by nASP, an initial study tested the effect of
the protease on TT. nASP prolonged ﬁbrinogen TT in a dose- and
enzymatic activity-dependent manner at concentration 10 nM or
greater, while the TT prolongation activity of nASP was signiﬁ-
cantly lower than that of sASP (Fig. 2A). Interestingly, testing in
plasma, the physiological source of ﬁbrinogen, nASP prolonged
the plasma TT more than sASP (Fig. 2B). Since ASP does not convert
plasminogen to plasmin [18], plasmin is not involved in ﬁbrinogen
degradation by ASP in plasma. This result indicated that nASP was
more ﬁbrinogenolytic in plasma than sASP. The next experiment
determined whether nASP activated prothrombin, as was found
with sASP [9]. nASP generated thrombin from prothrombin but it
was about 40% less effective than sASP (Fig. 3A). Prothrombin acti-
vation in plasma was investigated by measuring the PT of nASP-
treated plasma. PT is a measure of the extrinsic coagulation path-
way and ASP did not activate factor VII, IX or X [9], indicating that
ASP shortened plasma PT solely via prothrombin activation. nASP
was more potent than sASP in plasma PT shortening activity
(Fig. 3B). These results suggested the greater proteolytic activity
of nASP compared with sASP in plasma.
3.3. Effects of a2-MG on nASP
Lowered proteolytic activity of nASP in comparison with sASP
may be the same for cleavage of a2-MG bait region. Lowered bait
region cleavage would lead to lowered inhibition by a2-MG and
augment proteolytic activity in plasma. To compare the inhibition
by a2-MG, complex formation of ASP with a2-MG was analyzed by
SDS–PAGE. Both ASPs formed a complex with a2-MG (Fig. 4A).However, nASP formed the complex more slowly and free nASP
still remained after 90 s (Fig. 4A, lane h), whereas free sASP disap-
peared almost completely in 90 s (Fig. 4A, lane d). This demon-
strated the slower inhibition of nASP by a2-MG. The inhibitory
effect of a2-MG on ASP proteolytic activity was investigated by
testing ﬁbrinogen degradation by ASP in the presence of a2-MG.
nASP prolonged TT more than sASP at increasing a2-MG concentra-
tions, starting from 10 nM (Fig. 4B). a2-MG is a thrombin inhibitor,
so it may prolong TT by inhibiting the thrombin added to induce
ﬁbrin clotting. However, a2-MG did not affect TT, even at 30 nM
(data not shown). Thus, the greater effect of nASP on ﬁbrinogen
degradation under a2-MG control suggested that nASP could keep
its proteolytic activity for longer in plasma due to slower inhibition
by a2-MG.
3.4. Complex formation of nASP with a2-MG in plasma
To investigate nASP inhibition by a2-MG in plasma, ﬂuores-
cence-labeled nASP was added to plasma and the DT was measured
by FCS. The ratio of the larger DT value that corresponds to ASP-a2-
MG, in the total ﬂuorescence value, increased time-dependently
and nASP complex formation with a2-MG was slower than sASP
(Fig. 5). The 50% complex formation time estimated from the
approximation curves were about 180 s in sASP and 400 s in nASP.
The result suggested that nASP was inhibited by a2-MG more than
twofold slower than sASP in plasma.
4. Discussion
Comparison of nASP and sASP revealed the effects of the nick on
ASP protease activity as follows: (1) essentially negligible effect on
oligopeptide substrate cleavage activity (Table 1), (2) slight but sig-
niﬁcant reduction in the proteolytic activity (Figs. 2A and 3A),
which matched the low prekallikrein cleavage activity of nASP
compared with sASP [15], (3) increase of proteolytic activity in
plasma (Figs. 2B and 3B), due to retarding inhibition by a2-MG
(Figs. 4 and 5). These results show for the ﬁrst time that a bacterial
protease can mitigate a2-MG inhibition by nicking the tail region,
thereby enhancing its proteolytic activity in plasma.
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Fig. 2. ASP ﬁbrinogen degradation measured by thrombin time (TT). Ninety microliters of human ﬁbrinogen (3 mg/ml) (A) or citrated plasma (B) was incubated with 10 ll
protease at 37 C for 3 min, followed by the addition of 100 ll human thrombin (5 U/ml) to initiate clotting. Values are the mean ± S.D. (n = 4). Gray areas indicate the range
for controls that were assayed using TBS, instead of ASP. (s), sASP; (d), nASP; (4), sASP boiled for 5 min; (N), nASP boiled for 5 min. ⁄p < 0.01 for nASP versus sASP.
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Fig. 3. Activation of prothrombin by ASP. (A) Thrombin activity assay using a MCA substrate. Ninety microliters of prothrombin (1.1 lM dissolved in 50 mM Tris–HCl, pH 7.4,
containing 0.1 M NaCl and 5 mM CaCl2) was incubated with 10 ll of ASP at 37 C and then added to 500 ll of 0.1 M Tris–HCl, pH 7.6, containing 150 mMNaCl. To this mixture,
5 ll of Boc-Asp(OBzl)-Pro-Arg-MCA (10 mM) was added and the AMC released was measured. (B) Prothrombin time (PT) assay. Forty-ﬁve microliters of plasma and 5 ll of
ASP were incubated at 37 C for 3 min, followed by the addition of 50 ll of Thromborel S to initiate clotting. Values are the mean ± S.D. (n = 4). Gray area indicates the range
for controls that were assayed using TBS, instead of ASP. Symbols are the same as those used in Fig. 2. ⁄p < 0.01 for nASP versus sASP.
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Fig. 4. A, Trapping of ASP by a2-MG. ASP (70 nM) and a2-MG (84 nM) were incubated at 37 C, followed by the addition of 10 mMDFP for various time periods and analysis by
SDS–PAGE using an 8% polyacrylamide gel. A Silver Stain II kit was used for protein staining. Lane a indicates sASP alone and lanes b–d indicate sASP incubated with a2-MG for
10, 30 or 90 s, respectively. Lane e indicates nASP alone and lanes f–h indicate nASP incubated with a2-MG for 10, 30 or 90 s, respectively. Lane i indicates a2-MG alone. (B)
Inhibition of ASP ﬁbrinogen degradation by a2-MG. Ten microliters of 300 nM ASP was added to 90 ll of the mixture of ﬁbrinogen (3 mg/ml) and increasing concentrations of
a2-MG. After incubating at 37 C for 3 min, thrombin time was measured by the addition of 100 ll of human thrombin (5 U/ml). Values are the mean ± S.D. (n = 4). Gray area
indicates the range for controls that were assayed using TBS, instead of ASP. (s), sASP; (d), nASP. ⁄p < 0.01 for nASP versus sASP.
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in b-thrombin, which is converted from a-thrombin by cleaving off
the peptide Ile63-Arg73 in the B-chain [24]. The equivalence of b-
thrombin to a-thrombin in esterase activity [25] agrees with that
ASP activity for oligo-peptide substrates was essentially un-
changed after being nicked (Table 1). nASP showed only a slight
decrease in ﬁbrinogen clotting activity (Fig. 2A) and a 40% loss in
prothrombin activation activity (Fig. 3A), whereas the conversion
of bovine a-thrombin to b-thrombin resulted in a loss of approxi-
mately 90% of ﬁbrinogen clotting activity [26]. The cleavage site togenerate b-thrombin is situated between the active site residues
His43 and Asp97 in the B-chain [25], whereas the nASP nick be-
tween Gln519 and Leu520 is near the carboxy-terminus [15]
(Fig. 1). Thus, the nick may less affect the site where the catalytic
triad Asp78, His115 and Ser336 is located. In addition, as the ASP car-
boxy-terminal region is embedded in the protease body [15], ASP
conformation change is probably slight after being nicked. How-
ever, the ﬂexibility of the carboxy-terminal fragment was presum-
ably increased, which would interfere access of large molecular
substrates to the catalytic domain. Indeed, the nick decreased
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Fig. 5. Changes of a2-MG-trapped ASP ratio in plasma. Fluorescence-labeled ASP
(5 nM in PBS) was added to ﬁvefold-diluted plasma and the ratio of ﬂuorescence of
the larger DT value was measured. Values are the mean ± S.D. (n = 4). (s), sASP; (d),
nASP.
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trasted with the almost unchanged kcat values in the cleavage of
tripeptidyl p-nitroanilide substrates, b-thrombin exhibited in-
creased Km values compared with a-thrombin [27], indicating de-
creased b-thrombin afﬁnity to the substrate. Similarly, the nick of
nASP may cause decrease of the substrate afﬁnity to reduce prote-
olytic activity.
A protease is immediately trapped by a2-MG when it cleaves
the bait region of the inhibitor [28]. The retarded formation of
a2-MG complex with nASP (Fig. 4A) suggests slow cleavage of
the bait region by nASP, which is consistent with low proteolytic
activity of nASP for ﬁbrinogen and prothrombin (Figs. 2A and
3A). a2-MG is substantially only ASP inhibitor in human plasma
[16]. Plasma containing a2-MG leaks into interstitial tissues from
the bloodstream under physiological conditions and plasma leak-
age increases in inﬂammatory lesions, including sites of A. sobria
infections. ASP secreted from this pathogen is always under a2-
MG control. Slow inhibition by the sole regulator allows nASP to
maintain its proteolytic activity for longer in plasma compared
with sASP.
An A. sobria mutant strain that secretes non-proteolytic ASP
(H115A) also releases the ASP with a nick at the same site as the
nASP nick [15], indicating that nASP is not converted from sASP
by autocatalysis but instead that it is produced by the activity of
another A. sobria protease. To mitigate a2-MG control for ASP, this
pathogen might nick ASP at the tail region by its own protease,
augmenting ASP proteolytic activity in the infection sites. ASP vir-
ulence is dependent on its proteolytic activity. Thus, nASP substan-
tially elevates A. sobria virulence activities, such as pus formation
[11], the induction of septic shock [11,13] and blood coagulation
disorder [9,14], thereby exacerbating diseases caused by A. sobria
infections. nASP may be an example of bacterial protease evolu-
tionary change for this purpose.
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